Cargando…
Clinical Characteristics and Outcomes of Acute Lymphoblastic Leukemia in Adolescents and Young Adults in Malawi
There are limited data on treatment and outcomes for acute lymphoblastic leukemia (ALL) among adolescents and young adults in sub-Saharan Africa. We describe a prospective observational cohort in Malawi. METHODS: Patients age 15-39 years with newly diagnosed ALL at Kamuzu Central Hospital, Malawi, w...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276115/ https://www.ncbi.nlm.nih.gov/pubmed/35772043 http://dx.doi.org/10.1200/GO.21.00388 |
_version_ | 1784745644976504832 |
---|---|
author | Kasonkanji, Edwards Kimani, Stephen Skiver, Brent Ellis, Grace Seguin, Ryan Kaimila, Bongani Tomoka, Tamiwe Mulenga, Maurice Montgomery, Nathan Fedoriw, Yuri Gopal, Satish Westmorland, Katherine D. Painschab, Matthew S. |
author_facet | Kasonkanji, Edwards Kimani, Stephen Skiver, Brent Ellis, Grace Seguin, Ryan Kaimila, Bongani Tomoka, Tamiwe Mulenga, Maurice Montgomery, Nathan Fedoriw, Yuri Gopal, Satish Westmorland, Katherine D. Painschab, Matthew S. |
author_sort | Kasonkanji, Edwards |
collection | PubMed |
description | There are limited data on treatment and outcomes for acute lymphoblastic leukemia (ALL) among adolescents and young adults in sub-Saharan Africa. We describe a prospective observational cohort in Malawi. METHODS: Patients age 15-39 years with newly diagnosed ALL at Kamuzu Central Hospital, Malawi, were enrolled from 2013 to 2019; follow-up was censored on December 2020. ALL diagnosis was confirmed on-site using immunohistochemistry and telepathology consultation involving pathologists in Malawi and the United States. All but four patients were treated with a modified pediatric-inspired regimen (Cancer and Leukemia Group B 10403 protocol). Key modifications included omission of asparaginase and no dose escalation for methotrexate. RESULTS: Of 19 participants, the median age was 22 (range 15-36) years. Of the 15 patients who initiated treatment, 11 (73%) achieved remission after induction, one (7%) died during induction, two (13%) had refractory disease, and one (7%) absconded. No patients were lost to follow-up. Eventually, 10 of 11 patients (91%) with confirmed remission relapsed. The median duration of first remission was 10 (range 3-22) months. Twelve of 15 treated patients (80%) had died at the time of censoring. Among treated patients, the 12- and 24-month overall survival was 50% (95% CI, 23 to 72) and 17% (95% CI, 3 to 42), respectively. CNS involvement was associated with worse survival. CONCLUSION: It is possible to treat adolescents and young adults with ALL in low-resource settings using a low-cost, pediatric-inspired regimen; however, outcomes are poor. Both cost and limitations in supportive care infrastructure limit intensive cytotoxic approaches such as asparaginase. Patient-reported outcomes are needed to understand the quality of life and cost-effectiveness. Critically, innovative, leap-frog therapies, such as monoclonal or bispecific antibodies, and feasible economic models for resource-limited settings are urgently needed. |
format | Online Article Text |
id | pubmed-9276115 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-92761152022-07-13 Clinical Characteristics and Outcomes of Acute Lymphoblastic Leukemia in Adolescents and Young Adults in Malawi Kasonkanji, Edwards Kimani, Stephen Skiver, Brent Ellis, Grace Seguin, Ryan Kaimila, Bongani Tomoka, Tamiwe Mulenga, Maurice Montgomery, Nathan Fedoriw, Yuri Gopal, Satish Westmorland, Katherine D. Painschab, Matthew S. JCO Glob Oncol ORIGINAL REPORTS There are limited data on treatment and outcomes for acute lymphoblastic leukemia (ALL) among adolescents and young adults in sub-Saharan Africa. We describe a prospective observational cohort in Malawi. METHODS: Patients age 15-39 years with newly diagnosed ALL at Kamuzu Central Hospital, Malawi, were enrolled from 2013 to 2019; follow-up was censored on December 2020. ALL diagnosis was confirmed on-site using immunohistochemistry and telepathology consultation involving pathologists in Malawi and the United States. All but four patients were treated with a modified pediatric-inspired regimen (Cancer and Leukemia Group B 10403 protocol). Key modifications included omission of asparaginase and no dose escalation for methotrexate. RESULTS: Of 19 participants, the median age was 22 (range 15-36) years. Of the 15 patients who initiated treatment, 11 (73%) achieved remission after induction, one (7%) died during induction, two (13%) had refractory disease, and one (7%) absconded. No patients were lost to follow-up. Eventually, 10 of 11 patients (91%) with confirmed remission relapsed. The median duration of first remission was 10 (range 3-22) months. Twelve of 15 treated patients (80%) had died at the time of censoring. Among treated patients, the 12- and 24-month overall survival was 50% (95% CI, 23 to 72) and 17% (95% CI, 3 to 42), respectively. CNS involvement was associated with worse survival. CONCLUSION: It is possible to treat adolescents and young adults with ALL in low-resource settings using a low-cost, pediatric-inspired regimen; however, outcomes are poor. Both cost and limitations in supportive care infrastructure limit intensive cytotoxic approaches such as asparaginase. Patient-reported outcomes are needed to understand the quality of life and cost-effectiveness. Critically, innovative, leap-frog therapies, such as monoclonal or bispecific antibodies, and feasible economic models for resource-limited settings are urgently needed. Wolters Kluwer Health 2022-06-30 /pmc/articles/PMC9276115/ /pubmed/35772043 http://dx.doi.org/10.1200/GO.21.00388 Text en © 2022 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/Licensed under the Creative Commons Attribution 4.0 License http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | ORIGINAL REPORTS Kasonkanji, Edwards Kimani, Stephen Skiver, Brent Ellis, Grace Seguin, Ryan Kaimila, Bongani Tomoka, Tamiwe Mulenga, Maurice Montgomery, Nathan Fedoriw, Yuri Gopal, Satish Westmorland, Katherine D. Painschab, Matthew S. Clinical Characteristics and Outcomes of Acute Lymphoblastic Leukemia in Adolescents and Young Adults in Malawi |
title | Clinical Characteristics and Outcomes of Acute Lymphoblastic Leukemia in Adolescents and Young Adults in Malawi |
title_full | Clinical Characteristics and Outcomes of Acute Lymphoblastic Leukemia in Adolescents and Young Adults in Malawi |
title_fullStr | Clinical Characteristics and Outcomes of Acute Lymphoblastic Leukemia in Adolescents and Young Adults in Malawi |
title_full_unstemmed | Clinical Characteristics and Outcomes of Acute Lymphoblastic Leukemia in Adolescents and Young Adults in Malawi |
title_short | Clinical Characteristics and Outcomes of Acute Lymphoblastic Leukemia in Adolescents and Young Adults in Malawi |
title_sort | clinical characteristics and outcomes of acute lymphoblastic leukemia in adolescents and young adults in malawi |
topic | ORIGINAL REPORTS |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276115/ https://www.ncbi.nlm.nih.gov/pubmed/35772043 http://dx.doi.org/10.1200/GO.21.00388 |
work_keys_str_mv | AT kasonkanjiedwards clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi AT kimanistephen clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi AT skiverbrent clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi AT ellisgrace clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi AT seguinryan clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi AT kaimilabongani clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi AT tomokatamiwe clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi AT mulengamaurice clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi AT montgomerynathan clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi AT fedoriwyuri clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi AT gopalsatish clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi AT westmorlandkatherined clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi AT painschabmatthews clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi |